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The proteolytic F,, fragment of the well characterized antibody McPC603 was compared to the recombinant Fab fragment, which was obtamed 
in functional form from an Escherichiu coli expression system [(l989) Methods Enzymol. 178, 497-5151. We found evidence that the proteolytic 
fragment is glycosylated at Asn HI60 in the CHI domain, where additional electron density had been observed in the crystal structure [J. Mol. 
Biol. 190, 593-6041. In addition, its heavy chain is about 30 amino acids longer than visible in the electron density and thus contains the complete 
hmge region. These structural differences between the recombinant F,,,, fragment, which had been designed exactly according to the defined electron 
density. and the proteolytic F ,%b fragment of McPC603 had no effect on the hapten binding properties of these antigen binding fragments. Yet, 
it may be important to be aware of these structural features of McPC603 in folding studies and some comparative analyses of antibody structures. 
Antibody: E. cob, expression; Glycosylatlon: X-ray crystallography 
1. INTRODUCTION 
The Fab fragment of the phosphorylcholine-binding 
myeloma protein McPC603 [1,2] has been one of the 
first antibody fragments the X-ray structure of which 
was solved [3]. The structure of both the uncomplexed 
molecule and the Fab fragment with the hapten 
phosphorylcholine bound was determined to atomic 
resolution [4]. The affinities of the antibody McPC603 
for phosphorylcholine [5] and various related haptens 
[6,7] have been determined. McPC603 belongs to a 
family of genetically related myeloma proteins that all 
bind the hapten phosphorylcholine (PC) [1,2]. The 
members of this family MOPC167 and TEPC15 [8] as 
well as the recombinant F, fragment of McPC603 [9] 
were recently shown to possess catalytic activity 
towards hydrolysis of choline carbonate esters. 
We have now compared the properties of the recombi- 
nant F,t, fragment purified from E. coli with those of 
the proteolytic Fab fragment, obtained by limited diges- 
tion of the antibody McPC603 with pepsin. This ex- 
tends our previous work on the physical 
characterization of recombinant antibody fragments 
[13,14], as the Fab fragment does not dissociate at high 
dilution like the F, fragment [14]. 
2. MATERIALS AND METHODS 
We chose the antibody McPC603 as a model system 
for investigating the fundamentals of hapten binding 
and transition state stabilization by antibodies as well 
as the folding behavior of its fragments by protein 
engineering [9-l 11. For the rapid generation and 
preparation of mutant immunoglobulins we developed 
a system for the functional expression of both the F, 
and the Fab fragment of McPC603 in E. coli [12,13]. 
2.1. Purification of native antibody and proreolytic Fob fragment 
Native antibody McPC603 [l] was purified from mouse ascites 
fluid by phosphorylcholine affinity chromatography as described 
[15]. The Fab fragment was prepared from McPC603 according to 
Rudikoff et al. [16] by a limited proteolytic digest of the partially 
reduced antibody with pepsin, followed by gel filtration. The pro- 
teolytic Fab fragment was finally purified to homogeneity by 
phosphorylcholine affinity chromatography as above. 
2.2. Expression and purification of recombinant F;b fragment 
The recombinant Fuh fragment was expressed in E. coli strain 
W3110 harboring the plasmid pASK19 [12], which carries the struc- 
tural genes encoding the light and the heavy chain of the Fab fragment 
of McPC603 [lo]. The recombinant Fab fragment was purified as a 
functional protein from the periplasmic fraction of the E. coli cells 
by phosphorylcholine affinity chromatography as described 
previously [15]. 
2.3. Deglycosylarion 
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For the deglycosylation reaction, the proteins were dissolved in 
30 hl buffer I (0.2 M borate/NaOH (pH 8.0); 160 mM NaCl; 0.33% 
SDS (w/v); 1.66% 2-mercaptoethanol (v/v)) at an approximate con- 
centration of 1 mg/ml and denatured by heating to 100°C for 5 min. 
The samples were then cooled on ice and a solution of both 0.1 U en- 
doglycosidase F and 1.7 to 2.5 U N-glycosidase F (both Boehringer 
Mannheim) in 20~1 buffer II (0.2 M borate/NaOH (pH 8.0); 
160 mM NaCl) was added. The reaction mixtures were incubated at 
37’C for 24 h. An aliquot of this solution was directly loaded onto 
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an SDS polyacrylamide gel [17]. The proteins were detected by silver 
staining (‘Quick silver’ staining kit, Amersham). 
2.4. Hapten binding constants 
Hapten binding constants were measured by fluorescence titration 
as described previously [14]. 
2.5. Amino sugar analysis 
The Fab fragment was hydrolyzed with 4 M HCI for 6 h and amino 
sugars were detected with ninhydrin on a Beckmann amino acid 
analyzer 6300 according to the manufacturer’s instructions. 
2.6. C-terminal analysis with carboxypeptidase 
The carboxypeptidase digestion of the proteolytic Fat, fragment 
was performed using the method of Oberthur and Lottspeich (Ober- 
thiir and Lottspeich, manuscript in preparation). The Fab fragment 
was repeatedly treated with enzyme and separated after each incuba- 
tion from cleaved amino acids by a C4 Vydac mini-column. The 
amino acids were identified on a Beckmann Amino Acid Analyzer 
6300. 
3. RESULTS AND DISCUSSION 
The genes for the recombinant Fab fragment of 
McPC603 were designed to correspond exactly to the 
natural light chain and, in the case of the heavy chain, 
to the sequence visible in the electron density of the X- 
ray structure of the proteolytic Fab fragment [3,4]. 
Functional expression was achieved in E. coli with a 
plasmid [ 121, in which both genes are arranged in an ar- 
tificial operon under transcriptional control of the 
IPTG-inducible lac promoter, and both chains are fus- 
ed to bacterial signal sequences. Thus, both chains of 
the recombinant Fab fragment are secreted to the 
periplasmic space of E. coli where the disulfide bonds 
form and the functional Fab fragment assembles. 
The comparison of the recombinant Fab fragment 
with the proteolytic F,t, fragment by SDS-PAGE 
(Fig. 1) showed that the light chain had an identical 
mobility in the whole antibody (lane l), in the pro- 
teolytically prepared fragment (lane 3) and in the 
recombinant fragment (lane 5). The heavy chain of the 
proteolytically obtained Fab fragment, on the other 
hand, did not give rise to a band of the same mobility 
as in the recombined fragment (lane 5), but appeared to 
be larger (lane 3). 
In order to investigate whether the decreased elec- 
trophoretic mobility might be due to an N-linked 
&COSylatiOn, the proteolytic Fab fragment as well as 
the intact antibody McPC603 was treated with a 
preparation of endoglycosidase F that additionally con- 
tained N-glycosidase F [18,19]. After the glycosidase 
treatment, the mobility of the heavy chain of the intact 
antibody had significantly increased (lane 2) as ex- 
pected from the glycosylation within the F, region, In- 
terestingly, the mobility of the heavy chain of the Fab 
fragment had also increased (lane 4), thus 
demonstrating an N-glycosylation site within the Fd 
fragment. However, the mobility was still lower than 
that of the recombinant protein (Fig. 1). 
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Fig. 1. Comparison of recombinant and proteolytic F,b fragment as 
well as intact antibody McPC603 by SDS-PAGE (12.5%) under 
reducing conditions. (Lane 1) Intact antibody McPC603, (lane 2) 
deglycosylated antibody, (lane 3) proteolytic Fa,, fragment, (lane 4) 
deglycosylated proteolytic Fab fragment and (lane 5) recombinant Fah 
fragment from E. co/i. M denotes the molecular weight standard. 
The N-glycosylation site of the Fd fragment is most 
likely located within the Cwl domain, since the highly 
homologous antibody MOPCSll, also an IgA from 
mouse, had been shown to be N-glycosylated at the site 
corresponding to Asn H160 in McPC603 [20], a typical 
acceptor site [21]. Furthermore, Satow et al. [4] had 
noticed some additional electron density around Asn 
H160 in McPC603 and attributed it to glycosylation at 
this position. While there is another Asn-X-Thr site at 
position Asn H127, the middle amino acid X is proline, 
and this prevents N-glycosylation [22]. 
To eliminate the possibility of an additional O-linked 
glycosylation, which had been found in another mouse 
IgA at the position corresponding to Ser H223 [23], as 
the cause of the remaining discrepancy between the 
molecular weight of the recombinant and the N- 
glycosidase treated Fat, fragment, an amino sugar 
analysis was carried out as described in section 2. 
Glucosamine, but no galactosamine was detected, in- 
dicating the absence of O-linked glycosylation [24,25]. 
Therefore, pepsin cleavage must give rise to a larger 
heavy chain fragment than visible in the electron densi- 
ty. This observation is in complete agreement with 
previous results from pepsin cleavage of human IgA 
([26] and references cited there). An analysis of the 
heavy chain amino acid sequence shows that pepsin, 
whose preferred cleavage occurs between aromatic or 
leucine residues [27,28] is likely to predominantly 
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Fig. 2. Predominant cleavage site of pepsin in the heavy chain of 
McPC603 generating the Fat,’ fragment (filled arrow). The C- 
terminus of the recombinant heavy chain is indicated by the open 
arrow. 
cleave about 30 amino acids downstream from the end 
of the Cul domain (Fig. 2). The molecular weight of 
the corresponding fragment is entirely consistent with 
the observed mobility of the chains of the heavy chain 
of the glycosidase-treated Far, fragment on SDS-PAGE. 
While we cannot rule out that extensive pepsin diges- 
tion under different sets of conditions or a protease 
contaminant might further truncate the F,t, fragment, 
we have obtained no evidence for any shorter 
fragments. 
To confirm this interpretation, a carboxypeptidase 
digestion of the proteolytic Fat, fragment was perform- 
ed using the method of Oberthur and Lottspeich as 
described in section 2. The resulting time course of 
liberated amino acids indicated an immediate ap- 
pearance of leucine corresponding to about two 
mol/mol protein. This is consistent with pepsin 
cleavage as shown in Fig. 2. 
To investigate whether the binding function of the 
Fat, fragment depends in any way on these structural 
differences between recombinant and proteolytically 
prepared material, we compared the binding constants 
of the recombinant Fat, fragment and the proteolytical- 
ly prepared glycosylated F,t, ’ fragment for 
phosphorylcholine by fluorescence titration [ 141 
(Fig. 3). The binding constants so obtained were in- 
distinguishable for the recombinant Far, fragment (1.62 
x 10’ M-l) and the proteolytic Fat, fragment (1.60 x 
lo5 M-l). This demonstrates that the slight differences 
observed previously between the recombinant F, frag- 
ment and the Fab’ fragment or the whole antibody are 
caused by a partial dissociation of the chains, depen- 
ding on the protein concentration [14], since these dif- 
ferences disappear completely if the chains are 
prevented from dissociation, either by the presence of 
the constant domains as shown here, or by chemically 
crosslinking the F, fragment [ 141. 
Since the crystal structure of the Fat, fragment of 
McPC603 has been widely used in many comparative 
analyses of antibody structures and, because of its ex- 
tensive characterization, may serve as a model for pro- 
tein folding, it may be important to be aware of the 
glycosylation and the C-terminal extension of its heavy 
chain, neither of which was clearly visible in the elec- 
tron density map ([4]; E. Padlan and D. Davies, per- 
sonal communication). We could now show that these 
two differences between recombinant and proteolytic 
material have no influence on hapten binding. Our 
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Fig. 3. Scatchard plot of the binding of phosphorylchohne to 
recombinant (0) or proteolytically obtained Far, fragment (m). r 
denotes the fraction of antibody fragment with bound hapten and 
[PC] denotes the concentration of free phosphorylcholine. 
results thus demonstrate that functional Fat, fragments 
can be obtained from an E. coli expression system and 
that the lack of N-glycosylation in this expression host 
does not influence the hapten-binding properties of this 
antibody fragment. 
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